Benedict Paul C
What are the latest treatments available for Psoriasis? (On or before 26/12/2013)
Harini
Divya Gopal
- Scalp psoriasis
- Plaque psoriasis
- Inverse psoriasis
- Erythrodermic psoriasis
- Pastular psoriasis
- Palomar-plantar Pustulosis
- Guttate psoriasis
- Nail psoriasis
- Biologics: (Prescribed for moderate to severe psoriasis and psoriatic arthritis) Anti-tumor necrosis factor (anti-TNF) drugs are one type of biologic now used for psoriasis .Examples of anti-TNF drugs are:
- Adalimumab (Humira), approved for psoriasis and psoriatic arthritis
- Etanercept (Enbrel), approved for psoriasis and psoriatic arthritis
- Golimumab (Simponi), approved for psoriatic arthritis
- Infliximab (Remicade), approved for psoriasis and psoriatic arthritis
- Ustekinumab (Stelara) targets two proteins, interleukin-12 and interleukin-23, that help regulate the immune system.
- Adalimumab (Humira), approved for psoriasis and psoriatic arthritis
- Etanercept (Enbrel), approved for psoriasis and psoriatic arthritis
- Golimumab (Simponi), approved for psoriatic arthritis
- Infliximab (Remicade), approved for psoriasis and psoriatic arthritis
- Ustekinumab (Stelara) targets two proteins, interleukin-12 and interleukin-23, that help regulate the immune system.
More Psoriasis Medications on the Way
- 9-cis-beta-carotene, an oral beta-carotene to be combined with UVB light therapy for psoriasis.
- AMG 827, an injectable anti-inflammatory (IL-17 receptor blocker) for psoriasis.
- Apremilast, an oral anti-inflammatory (phosphodiesterase-4 inhibitor) for psoriasis and psoriatic arthritis.
- Briakinumab, an injectable anti-inflammatory (IL-12/-23 blocker) for psoriasis.
- Certolizumab pegol (Cimzia), an injectable anti-inflammatory (TNF blocker) for psoriatic arthritis. This drug is FDA approved for treatment of rheumatoid arthritis and Crohn’s disease.
- CF101, an oral anti-inflammatory (adenosine A3 receptor inhibitor) for psoriasis
- Desoximetasone, a topical anti-inflammatory (steroid) for psoriasis.
- Indigo naturalis ointment, a traditional Chinese medicine for psoriasis.
- Tofacitinib, an oral anti-inflammatory (JAK kinase inhibitor) for psoriasis and psoriatic arthritis.
- Voclosporin, an oral immune suppressant (calcineurin blocker) for psoriasis.
source: http://www.webmd.com/skin-problems-and-treatments/psoriasis-treatment-13
Kani Mozhi
Psoriasis;
psoriasis is a common chronic condition causing redness, dryness, scaling, irritation and cell build-up on the surface of the skin. This produces thick, flaky scales that are white or silver in appearance. Itch and pain may exist, as well as swollen and stiff joints in extreme cases. Often, symptoms will first present between ages 15 to 35.
Types of psoriasis;
plague psoriasis.
guttate psoriasis.
inverse psoriasis.
pustular psoriasis.
erythrodermic psoriasis.
References;
www.latestpsoriasis treatment.com
Benedict Paul C
jyothi B
Biocon launches novel drug for psoriasis
August 10, 2013 | Anshul Dhamija , TNN
BANGALORE: Biocon has launched an injectable drug for patients suffering from moderate to severe psoriasis. The Bangalore-headquartered biopharmaceutical company says its novel drug Alzumab, which has been developed through a biological process, is a first of its kind in the world. The company said the drug offers patients a less aggressive dosing regime and a longer treatment-free period. Alzumab is priced at Rs 7,950 per vial.
After geting the regulatory approval in early 2013, Biocon, India's number two biotech company by revenues, released the much awaited Itolizumab with its brand name Alzumab in India.
The monocolonal anti-body, the second novel biological drug developed entirely in India, is an anti-CD6 antibody based product. "Biocon's Alzumab is the first anti-CD6 monoclonal antibody to be commercialized, an outcome of path breaking research in India," said Biocon's CMD, Kiran Mazumdar-Shaw, while launching the product in Bangalore on August 10.
"We are proud
that this will be the first instance of a breakthrough innovation from India
with a potential to treat multiple autoimmune diseases and making a difference
to a much larger patient population across the world."
Read more at: http://articles.timesofindia.indiatimes.com/2013-08-10/india-business/41266139_1_alzumab-biologic-psoriasis
Dhana
Goutham Kumar
Treatment for Psoriasis Patients in India
• ALZUMAbTM-World's first novel anti-CD6 antibody developed by Biocon to
address a large unmet need for the treatment of Psoriasis in India
• Excellent safety and efficacy profile with very low opportunistic infection rates
and longer remission period
• Offers a new treatment option for Psoriasis with a less aggressive dosing regimen
and a longer treatment free period, ensuring better patient compliance and
convenience
• Is an innovative affordable treatment option with a promise to offer a better
quality of life for the patient
• Will provide an effective biologic treatment solution to 1-2% of Indian
population suffering from Psoriasis
• ALZUMAbTM- (Itolizumab) has demonstrated preclinical and/clinical evidence in
treating other autoimmune diseases like rheumatoid arthritis, psoriatic arthritis
and multiple sclerosis.
• Biocon is committed to offering this novel anti -CD6 biologic from India to
patients across the globe.
See More at :
http://www.google.co.in/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCsQFjAA&url=http%3A%2F%2Fwww.biocon.com%2Fdocs%2FPR_Alzumab_10Aug2013.pdf%3FsubLink%3Dnews%26Fileid%3D467&ei=Me3HUov5HszzoASj5YKIAw&usg=AFQjCNF9KK_YYVfTImo45B82XMr-hcayFw&sig2=rnMH1YKZyOH_gr_yk00wOg&bvm=bv.58187178,d.cGU
Future Place of Anti-interleukin-17-based Strategies in Treatment of Psoriasis
IL-17A is a new and attractive therapeutic target in psoriasis. Blocking IL-17 reduces psoriasis-like pathology in animal models. In a proof-of-concept study and two phase II studies with the IL-17 inhibitors secukinumab and ixekizumab and the IL-17RA inhibitor brodalumab, each agent was effective in patients with plaque psoriasis. These studies, however, were neither large enough nor long enough to assess risks of infection or cardiovascular events. Results of ongoing phase III studies will be important in determining the advantages and disadvantages of blocking IL-17A as compared with molecular targets having broader impact on the immune system. It is likely that IL-17A inhibitors will be used initially in patients who are inadequate responders or intolerant of TNF-α blockers given the long-term clinical experience with these agents. However, as clinical experience grows with IL-17A inhibitors, they may supplant the TNF-α blockers as first-line biologic therapy if they show improved efficacy during induction and maintenance therapy and/or improved long-term safety with lower risk of infection and malignancy.
See More At:
http://www.medscape.com/viewarticle/772799_6
Harini
New Treatment for Psoriasis
The psoriasis treatment consists of a compound which, when applied to the skin, is absorbed by skin cells much more naturally than most other ointments. It contains a synthesised molecule based on the fatty acid docosahexaenoic acid (DHA) which may prove effective in inhibiting chronic inflammation associated with psoriasis.
Ref: http://www.sciencedaily.com/releases/2013/01/130111092533.htm
Acitretin |
Oral retinoid |
· First-line systemic drug for chronic palmoplantar or pustular psoriasis in patients of nonchildbearing potential · Limited benefit for plaque psoriasis |
Cyclosporine |
Oral calcineurin inhibitor |
· Fast-acting systemic drug that is often used first-line for von Zumbusch pustular psoriasis or erythrodermic psoriasis · For intermittent use in periods up to 12 weeks as a short-term agent to control a flare of psoriasis |
Methotrexate Sodium |
Inhibitor of folate biosynthesis |
· Methotrexate sodium Inhibitor of folate biosynthesis May be used as a first-line systemic drug for plaque psoriasis · Compared to cyclosporine, has a more modest effect, but can be used continuously for years or decades |
Adalimumab |
TNF inhibitor |
· May be used as a first-line systemic drug for plaque psoriasis · Has higher efficacy and has a lower rate of adverse effects compared with methotrexate |
Etanercept |
TNF inhibitor |
· Commonly used as a first-line systemic drug for chronic plaque psoriasis |
Infliximab |
TNF inhibitor |
· Intravenous infusion · Fast-acting drug that is often used as a second- or third-line biological for chronic plaque psoriasis |
Ustekinumab |
Monoclonal antibody that binds the shared p40 protein subunit of IL-12 and IL-23 |
· Favorable results when compared with etanercept in terms of efficacy and safety · May be used as a first-line treatment for chronic plaque psoriasis |
Alefacept* |
Interacts with T-cell surface proteins; acts in part by triggering the death of pathogenic T lymphocytes |
· For intermittent use · Little evidence to support use to achieve full clearance · Often used in combination regimens · May be used as first-line systemic drug for chronic plaque psoriasis |
Ref: http://www.psoriasis.org/new-treatment-guidelines
Drug promises total cure for psoriasis patients
KOLKATA: Researchers at the NRS Medical College and Hospital have developed a drug for psoriasis an auto-immune disease that leads to skin inflammation and rashes and has no definite cure that could lead to a complete recovery.
After an intensive five-year research and a series of experiments, including human clinical trials, the researchers claim to have arrived at a drug a plant extract which is non-toxic and infinitely more effective than existing drugs. Even though trials are over, no drug manufacturing company has so far shown interest.
Developed from an oil extract of pongamiapinata (koronjo), the drug prevents accumulation of tissues between dermis and epidermis layers of the skin that causes the disease. It occurs when the immune system sends out faulty signals that speed up the growth of skin cells. In plaque psoriasis, which is the most common of the five kinds of the disease, the skin rapidly accumulates at these sites giving it a silvery-white scale-like appearance. Drugs tend to have a short-term effect and are hepato-toxic, affecting liver and the kidneys.
A human trial was conducted on 100 patients with a 90% success rate.
Barring 10, the rest had a complete cure within 3 to 4 months. Periodic
examinations showed that they didn't suffer a relapse either.Despite being successful, the research paper remains unpublished.
Ref: http://articles.timesofindia.indiatimes.com
A New Era of Psoriasis Treatment
Research in psoriasis doesn’t make headlines -- or win funding -- like discoveries in cancer or heart disease. Also, psoriasis research is hamstrung by the uniqueness of human skin: Unlike in other diseases, experiments on mice or other animals aren’t very helpful. In recent years, though, psoriasis research funding by the National Institutes of Health has doubled. More broadly, research into other autoimmune diseases has yielded new knowledge about the immune system. It turns out some of the problems in other autoimmune illnesses are active in psoriasis, as well.
This greater understanding of immune system diseases has brought new treatments, targeted at specific aspects of the immune system. Called biologic agents, these drugs have launched a new era of treatment for psoriasis.
Biologic Agents as Psoriasis Treatment
Biologic agents are medicines made from substances found in living organisms. These lab-manufactured proteins or antibodies are injected into the skin or bloodstream. Once inside the body, the biologic agent blocks some part of the altered immune system that contributes to psoriasis.
In general, biologic agents improve psoriasis by:
· Suppressing T-cells (a form of white blood cell) directly
· Blocking a substance called tumor necrosis factor-alpha (TNF-alpha), one of the main messenger chemicals in the immune system
· Blocking a family of the immune system’s chemical messengers called interleukins
The patches and plaques of
psoriasis result from a dysfunctional interaction between skin cells and white
blood cells. By interfering with TNF-alpha or T-cells, or
targeting proteins called interleukins, biologic agents short-circuit the
unhealthy association between the two cell types. Inflammation (redness and
itch) and the
overgrowth of thick, scaly skin are both reduced.
The biologic agents approved by the FDA for treatment of moderate to severe psoriasis include:
· Etanercept (Enbrel), a TNF-alpha blocker
· Adalimumab (Humira), a TNF-alpha blocking antibody
· Infliximab (Remicade), a TNF-alpha blocker
· Ustekinumab (Stelara),a human antibody against interleukins
Biologic agents work well for treating psoriasis: in clinical trials, each of the medicines reduced psoriasis activity by at least 75% in many people. However, these new psoriasis medicines have drawbacks. Biologic agents for psoriasis treatment can cost hundreds or thousands of dollars per month. Although safe for most people, close monitoring is needed for an increased risk of infection, cancer, and other complications.
Ref: http://www.webmd.com/skin-problems-and-treatments/psoriasis/research
Biocon offers psoriasis treatment
Biocon has introduced a
therapy for treatment of psoriasis—a skin disease—claiming its offering
provides superior safety than other treatments. Psoriasis—formation of red
patches on skin—is a lifelong condition and does not have a cure yet. Through
treatments, its symptoms disappear for some time (this duration is known as
“remission period”). Announcing the launch of ALZUMAb on Saturday, Biocon CMD
Kiran Mazumdar-Shaw said the treatment is an outcome of path-breaking research
in India and would usher in a paradigm shift in treating psoriasis.
Rakesh Bamzai, president (marketing), Biocon, said the therapy offers better
safety, efficacy, longer remission period and lower infection rate. He said
these features would lead to overall reduction in cost burden to the patient. He
said a single dose of ALZUMAb is priced at Rs7,950 and the person suffering
from psoriasis has to undergo treatment for 24 weeks. Mazumdar-Shaw was asked
if the poor would get concession. She ruled it out, saying the company has to
recover the money it pumped in for research and development of the therapy.
Indicated for the treatment of moderate-to-severe psoriasis, ALZUMAb is being
introduced in India by Biocon’s immunotherapy division. Formulated as an
infusion drug it is manufactured at Biocon’s biopharma manufacturing facility
at Biocon Park, in Bangalore.
Divya Gopal
Treatment Options Expand for Psoriasis Patients
"Alzumab is a first in class novel biologic for psoriasis globally. We believe that the drug will change the treatment paradigm for psoriasis in India," said Kiran Mazumdar-Shaw, CMD, Biocon. The Rs 2,500 core company has spent about 10 years in research and development (R&D) of the drug.
Biocon gears up to offer in-house developed novel psoriasis drug AlzuMAb |
| Our Bureau, Bengaluru Monday, August 12, 2013, 13:40 Hrs [IST] Biocon Limited is gearing up to offer its in-house developed monoclonal antibody AlzuMAb which is world's first novel anti-CD6 antibody to address a large unmet need for the treatment of moderate-to-severe psoriasis in India. The drug safety and efficacy profile has very low opportunistic infection rates and longer remission period. Moreover the drug is reported to have a less aggressive dosing regimen and a longer treatment free period, ensuring better patient compliance and convenience. The drug is priced 50 per cent lower to the global companies which have a drug for psoriasis but not a first in class novel antibody. AlzuMAb or Itolizumab is the first anti-CD6 monoclonal antibody to be commercialised, an outcome of path breaking research in India. This new line of treatment will usher in a paradigm shift in the management of psoriasis. It has demonstrated preclinical and/clinical evidence in treating other autoimmune diseases like rheumatoid arthritis, psoriatic arthritis and multiple sclerosis. In fact, this will be the first instance of a breakthrough innovation from India with a potential to treat multiple autoimmune diseases and making a difference to a much larger patient population across the world, said Kiran Mazumdar-Shaw, chairperson and managing director, Biocon Limited at a press conclave. reference: http://www.pharmabiz.com/NewsDetails.aspx?aid=77104&sid=2 |
Kani Mozhi
New Treatment For Psoriasis Is Highly Effective
Current treatments for psoriasis include topical medicines and UV light therapy to treat the symptoms of the disease. Many of these treatments are messy, time consuming, have cumulative toxicities, and are not very effective, according to Gerald Krueger, M.D., principal investigator for the study. Krueger is a professor of dermatology and a Benning Presidential Endowed Chair at the University of Utah School of Medicine.
He says the results of the study are especially intriguing because of what it may mean for other immune mediated diseases that share the same signaling pathways, specifically inflammatory bowel disease (IBD).
In 2005 another team of researchers (Mannon et al for the anti-IL-12 Study Group) showed that a different human monoclonal antibody to p40 was effective in the treatment of IBD. "These results suggest that therapeutics that target the IL-12 and IL-23 signaling pathway appear to effectively treat both psoriasis and IBD," he said.
According to Krueger, the story of the link between psoriasis and IBD gains intrigue by events independent of these reports of treatment success. In October of last year the University of Utah and Celera Group of Applera Corporation reported at the American Association of Human Genetics annual meeting that psoriasis patients carry a common polymorphism in the gene for p40 (IL12B) more often than control subjects. Further exploration led to a discovery of a second polymorphism in the receptor for IL-23 that also associates with psoriasis. These results were recently published in the American Journal of Human Genetics (Cargill et al. 2007). Duerr and colleagues (2006) have reported that the same variant in the IL-23 receptor is associated with IBD. The common forms of these polymorphisms are associated with risk of both psoriasis and IBD, while the uncommon forms are protective, according to Krueger.
"This is really an alignment of the stars. It's unusual that targeting a new inflammatory pathway in two different diseases provides patients with dramatic improvement," he said. "And then, almost simultaneously, we find disease-associated genetic variants in this same pathway."
Krueger and colleagues at Celera predict that refinement of disease association patterns to specific genetic variants within IL-12/23 and the IL-23 receptor will play an important role in the elucidation of the causes of psoriasis, and IBD.
Krueger says that, "Further studies should help determine whether any of the identified differential risk polymorphisms are also associated with response to therapy and possible toxicities and thereby help determine the most effective dosage of these new monoclonal antibody therapies."
Researchers from Dalhousie University in Halifax, Nova Scotia; St. Louis University, St. Louis; Mount Sinai School of Medicine, New York; and Centocor, Inc. of Malvern, Penn.; participated in the study. The study published was funded by Centocor, Inc.